5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Europe Kidney Cancer Therapeutics & Diagnostics Market is segmented by Cancer Type, Component (Drugs and Diagnostics) and Geography.
2018 - 2026
The Europe Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.7% during the forecast period. The major factors driving the growth of the market in the Europe region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.
According to GLOBOCAN 2018, in Germany, there were about 16,416 new kidney cancer cases in 2018 and the mortality was approximately 8,450 cases.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Europe kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.
As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The Europe kidney cancer therapeutics & diagnostics market is segmented by cancer type, component and geography.
|By Cancer Type|
|Clear cell RCC|
|Urothelial carcinoma/Transitional cell carcinoma|
|Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)|
Report scope can be customized per your requirements. Click here.
Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles.
According to Kidney Cancer Care Ltd., Kidney cancer is the seventh most common cancer in the UK, which is responsible for around 12,600 new cases every year in the UK which equates to 34 cases every day and up to 30% of all people are diagnosed when in the advanced stage of the disease. Over the last decade kidney cancer incidence has risen by nearly half (47%) and is projected to rise by 26% in the UK between 2014 and 2035.
Furthermore, in 2017, EUSA Pharma and AVEO Oncology announced the first commercial launch of FOTIVDA (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC).
Hence, with high prevalence of the disease and presence of diagnostic procedures and treatment therapies, the segment is expected to witness growth.
To understand key trends, Download Sample Report
The Europe Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated competitive. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market. Some of the companies which are currently dominating the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, BRISTOL-MYERS SQUIBB COMPANY, Amgen Inc, Novartis AG, Pfizer Inc, and Seattle Genetics.
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Number of Kidney Cancer Cases
4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost Associated with Treatment
4.3.2 Preference for Generic Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Clear cell RCC
5.1.2 Papillary RCC
5.1.3 Chromophobe RCC
5.1.4 Urothelial carcinoma/Transitional cell carcinoma
5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
5.2 By Component
22.214.171.124 Therapeutic Class
126.96.36.199.1 Targeted Therapy
188.8.131.52.3 Other Therapeutic Class
184.108.40.206 By Pharmacologic Class
220.127.116.11.1 Angiogenesis Inhibitors
18.104.22.168.2 Monoclonal Antibodies
22.214.171.124.3 mTOR Inhibitors
126.96.36.199.4 Cytokine Immunotherapy (IL-2)
188.8.131.52 Imaging Tests
184.108.40.206 Blood Tests
220.127.116.11 Other Diagnostics
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 Bayer AG
6.1.4 Novartis AG
6.1.5 Amgen Inc
6.1.6 Abbott Laboratories
6.1.7 Cerulean Pharma Inc
6.1.8 Eisai co Ltd
6.1.9 Seattle Genetic
6.1.10 BRISTOL-MYERS SQUIBB COMPANY
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments